Evidence map›Paper›PMID 25929939›Full record

GuidelineEuropean radiology2015

ESR/ERS white paper on lung cancer screening.

Hans-Ulrich Kauczor, Lorenzo Bonomo, Mina Gaga, Kristiaan Nackaerts, Nir Peled, Mathias Prokop, Martine Remy-Jardin, Oyunbileg von Stackelberg, Jean-Paul Sculier, European Society of Radiology (ESR) and 1 more

Abstract readPractice Guideline
In one paragraph

Guideline in European radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2017
    Guideline
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. A Bibliometric Analysis of Comorbidity of COPD and Lung Cancer: Research Status and Future Directions.International journal of chronic obstructive pulmonary disease · 2023
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hans-Ulrich KauczorDept of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany, hans-ulrich.kauczor@med.uni-heidelberg.de.
Lorenzo Bonomo
Mina Gaga
Kristiaan Nackaerts
Nir Peled
Mathias Prokop
Martine Remy-Jardin
Oyunbileg von Stackelberg
Jean-Paul Sculier
European Society of Radiology (ESR)
European Respiratory Society (ERS)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledLung cancer is the most frequently fatal cancer, with poor survival once the disease is advanced. Annual low-dose computed tomography has shown a survival benefit in screening individuals at high risk for lung cancer. Based on the available evidence, the European Society of Radiology and the European Respiratory Society recommend lung cancer screening in comprehensive, quality-assured, longitudinal programmes within a clinical trial or in routine clinical practice at certified multidisciplinary medical centres. Minimum requirements include: standardised operating procedures for low-dose image acquisition, computer-assisted nodule evaluation, and positive screening results and their management; inclusion/exclusion criteria; expectation management; and smoking cessation programmes. Further refinements are recommended to increase quality, outcome and cost-effectiveness of lung cancer screening: inclusion of risk models, reduction of effective radiation dose, computer-assisted volumetric measurements and assessment of comorbidities (chronic obstructive pulmonary disease and vascular calcification). All these requirements should be adjusted to the regional infrastructure and healthcare system, in order to exactly define eligibility using a risk model, nodule management and a quality assurance plan. The establishment of a central registry, including a biobank and an image bank, and preferably on a European level, is strongly encouraged. KEY POINTS: • Lung cancer screening using low dose computed tomography reduces mortality. • Leading US medical societies recommend large scale screening for high-risk individuals. • There are no lung cancer screening recommendations or reimbursed screening programmes in Europe as of yet. • The European Society of Radiology and the European Respiratory Society recommend lung cancer screening within a clinical trial or in routine clinical practice at certified multidisciplinary medical centres. • High risk, eligible individuals should be enrolled in comprehensive, quality-controlled longitudinal programmes.

Indexed as

Early Detection of CancerEuropeHumansLung NeoplasmsTomography, X-Ray Computed

Identifiers

PMID25929939
PMCPMC4529446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.